PLx Pharma is a pharmaceutical company focused on its PLxGuard drug delivery platform. Co.'s PLxGuard delivery system targets the release of active pharmaceutical ingredients to various portions of the gastrointestinal tract. Co.'s primary product, VAZALORE 325 mg, has been approved by the FDA for liquid-filled aspirin capsule. In clinical trials in obese diabetic patients at risk for cardiovascular disease, VAZALORE 325 mg delivered platelet inhibition consistent with immediate release aspirin. VAZALORE 81 mg is Co.'s lower-dose companion product for VAZALORE 325 mg. This product utilizes the same formulation as the 325 mg product (except delivered in a capsule one quarter the size). The PLXP stock yearly return is shown above.
The yearly return on the PLXP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PLXP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|